Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2Thoracic 1NET 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Neuroendocrine Tumors 3Pheochromocytoma 2Paraganglioma 2Neoplasm Metastasis 2Uveal Melanoma 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Adrenocortical Carcinoma 1Adrenocortical Adenoma 1Adenoma, Islet Cell 1Adenocarcinoma of Lung 1

Interventions

3-Iodobenzylguanidine 14Temozolomide 6lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4anlotinib 4Specimen Handling 4Everolimus 4Radiotherapy 3Phenoxybenzamine 3Magnetic Resonance Spectroscopy 3Doxorubicin 36-fluorodopamine 33-fluorobenzylguanidine 3pegfilgrastim 2olaparib 2fluorodopa F 18 2cabozantinib 2belzutifan 2Nivolumab 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Biopsy 2Axitinib 2Adrenalectomy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pheochromocytoma × Biopsy × Endocrine × Clear all
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡